Follow The Filings

QNRX Quoin Pharmaceuticals

Quoin Pharmaceuticals earnings company data as of 10:00 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —
FY2026 Q2 14 Aug EPS — -1.90 —
Rev — — —

Insider trades

Open-market buys and sales by QNRX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All QNRX insider trades
  • $280K bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Denise P. Carter COO
    Buy
    $100K 20,490 shares at $4.88 +119% to stake
    Traded Aug 31 Filed Sep 1
    ↗
  2. Sally Bridget Lawlor CFO
    Buy
    $50K 10,244 shares at $4.88 +2328% to stake
    Traded Aug 31 Filed Sep 1
    ↗
  3. Anthony James Culverwell Director
    Buy
    $30K 6,146 shares at $4.88 +18% to stake
    Traded Aug 31 Filed Sep 1
    ↗
  4. Dennis Langer Director
    Buy
    $129K 15,152 shares at $8.49 +1515200% to stake
    Traded Oct 14, 2025 Filed Oct 15, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 2 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
424B3 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 1.01,3.02,7.01,8.01,9.01 Filing Doc
8-K 5.02,5.07,8.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
424B3 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 7.01,8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.